Background/Aims: Blood pressure variability (BPV) is a novel cardiovascular risk factor for the population undergoing hemodialysis (HD). Methods: We conducted a retrospective cohort study of 526 HD patients. Four short-term peridialysis BPV metrics were analyzed: systolic blood pressure (SBP) change, SBP coefficient of variation (CV), SBP intradialytic average real variability (ARV), and absolute SBP residual. Multi variate analysis with Cox regression models were used to account for the potential confounders. Results: Short-term BPV is found to be affected by age, pre-dialysis SBP, antihypertensive drugs, dialysis time, and vascular access. Calcium-channel blockers (CCBs) were found to be associated with lower BPV than those on non-CCB therapy or no antihypertensive drugs. Patients dialyzed in the morning had a greater absolute SBP change than those dialyzed in the afternoon or evening. Patients using fistulas had a lower BPV than catheters. Higher BPV metrics including SBP CV (unadjusted hazard ratio [HR]: 1.37, 95% confidence interval [CI] 1.14-1.66, p=0.001), SBP intradialytic ARV (unadjusted HR: 1.46, 95% CI: 1.20-1.77, p<0.001), and SBP residual (unadjusted HR: 1.47, 95% CI: 1.21-1.79, p<0.001) were associated with a greater risk of cardiovascular events. After complete multivariate adjustment for other potential confounders, the HR remained statistically significant for SBP intradialytic ARV (HR 1.31, 95% CI: 1.04-1.66, p=0.024). Conclusion: Peridialytic BPV may be a potential target for improved blood pressure (BP) management in HD patients. Each short-term BPV metric has different advantages and disadvantages and should be applied according to the clinical context and purpose.
Introduction
Hypertension is the leading preventable risk factor for cardiovascular disease and death. Owing to its impact, even minor refinements in observance parameters can have a potentially huge impact on patient survival [1] . Accumulative evidence suggests that apart from average blood pressure (BP), blood pressure variability (BPV), which is a measure of BP fluctuations over time, is associated with cardiovascular outcomes in general hypertensive patients [2] [3] [4] [5] [6] . It is differentiated into short-term (within 24 hours), mid-term (day-by-day), and long-term (visit-to-visit) BPV based on the time interval [7] .
Hemodialysis (HD) patients have a 10-to 20-fold increased risk for cardiovascular diseases than general population [8] . Part of the reason could be the dialysis procedure that creates a stress on the cardiovascular system and thereby leading to progressive organ damage. Clinical experience dictates that HD patients are particularly prone to increased BPV as denoted by ambulatory blood pressure monitoring (ABPM) [9] , suggesting that BPV may contribute to their burden of cardiovascular disease. Toward this direction, several studies exploring the relationship between BPV and cardiovascular outcomes in HD patients have been reported. Most studies focused on long-term BPV and demonstrated the association between long-term BPV and cardiovascular disease [10] and mortality [11, 12] . Short-term BPV is less studied and lacks a proper clinically relevant measurement. Flythe et al. defined a measure for intradialytic short-term BPV using absolute regression residuals from a mixed-effect model and suggested that greater short-term BPV could be a predictor of cardiovascular and all-cause mortality in HD patients [13] . However, the short-term BPV metric used in their study was too complex to be implemented in clinical practice.
The intermittent nature of HD is believed to play an important role in the fluctuation of BP. Besides, researchers have found out many other factors associated with BPV, including age, dialytic sessions, and dialytic frequency [14] [15] [16] [17] [18] .
Further, the effect of the antihypertensive drug class on BPV is not yet understood. While a French study concluded calcium-channel blockers (CCBs) to be better for controlling BPV, a Japanese study conducted on peritoneal dialysis patients showed angiotensin receptor blockers (ARBs) to be better in controlling BPV [19, 20] .
No clear metric with superior predictive power and operational threshold for peridialytic short-term BPV is available to assess cardiovascular risk and BP management in HD patients. Hence, we conducted a retrospective cohort study in Chinese HD patients to assess four different peridialytic short-term BPV metrics and their association with cardiovascular outcomes in HD patients.
Materials and Methods

Study design and population
We performed a retrospective cohort study of patients who commenced maintenance hemodialysis (MHD) between January 1. 2014 and December 31, 2014 at the Dialysis Center of West China Hospital. Renal failure patients aged ≥18 years undergoing MHD in-center on a twice-or thrice-weekly basis for at least 3 months were included in the study. Patients were excluded if they were on dialysis for <2 or >8 hours, if they received a renal transplant, or if their BP measurement data were not available. Written consent was obtained from all patients. Patients were monitored until December 31, 2017, the closing date of the study, or until their death, whichever is earlier, and were withdrawn from the study at the time of kidney transplantation. The study was performed in accordance with the principles of the Declaration of Helsinki and was approved by the Ethics Committee of the West China Hospital.
Data collection
Demographic characteristics (e.g., age, gender, height, body mass index, dialysis vintage, and vascular access type), comorbidities (diabetes, hypertension, heart failure, and coronary artery disease), and a complete list of medications with their dosage were obtained from West China Hospital's electronic medical registry. Comorbidities were considered as of cohort entry, and patient compliance toward medication was not assessed.
BP was measured four to six times per dialysis session, with the patient in the seated position using automated BP cuff just before ("pre-dialysis"), immediately after ("post-dialysis"), and during (typically at 1-hour intervals) dialysis. SBP measurements were taken during each dialysis session for all patients. All BP data for 2014 were extracted from the electronic medical registry. Mean values of all BP parameters during the first baseline year were considered as patients' baseline BP parameters. Laboratory parameters including hemoglobin, blood glucose, triglycerides (TGs), uric acid, albumin, creatinine, calcium, and parathyroid hormone (PTH) levels were measured at the time of enrolling and then on a bimonthly or trimonthly basis throughout the study period. The mean values over the study period for different laboratory parameters were considered for further analysis.
To find the impact of different classes of antihypertensive drugs on short-term BPV, patients were divided into five treatment groups: (1) CCB group, receiving either CCBs alone or in combination with non-ACEI/ARB antihypertensive drugs; (2) ACEI/ARB group, receiving either ACEI/ARB alone or in combination with non-CCB antihypertensive drugs; (3) CCB + ACEI/ARB group, receiving both CCBs and ACEI/ARBs; (4) non-CCB and non-ACEI/ARB group, receiving antihypertensive drugs other than CCBs and ACEI/ARBs; and (5) patients who were not on antihypertensive drugs. A threshold of 6 months in-treatment during a 1-year baseline visit was considered for categorizing patients into different antihypertensive drug groups.
The co-primary outcomes of interest were cardiovascular events and all-cause mortality. The first occurrence of a cardiovascular event such as coronary heart disease, myocardial infarction, or heart failure was documented. All-cause mortality was defined as death due to any cause. Death due to cardiovascular cause alone was also documented.
Definition and assessment of BPV
We analyzed four different metrics of peridialytic short-term BPV in this study: (1) SBP change, which is the mean difference between post-dialysis SBP and pre-dialysis SBP that represents the gross BP fluctuation/change during dialysis; (2) coefficient of variation (CV) of SBP (CV = standard deviation of SBP/mean SBP); (3) intradialytic average real variability (ARV) of SBP, which is obtained averaging the differences in successive BP readings taken during each dialysis session, is a better indicator of temporal SBP variation [21] and is calculated as ARV= , where N is the number of SBP measurements taken during each dialysis session, which is 5 in this study; and (4) absolute SBP residual, a measure of intradialytic SBP variability, which is calculated from a previously described mixed linear model which takes into account the starting SBP, systematic change in SBP during each dialysis session, and random variability in SBP, is calculated as the baseline BP measurements for all the dialysis sessions during 2014, which were incorporated into the mixed effects model to create a predicted pattern of SBP fluctuation during each dialysis session. The absolute difference of this predicted and observed values averaged over treatment sessions and patients is the absolute SBP residual metric [13] .
Statistical analysis
The different baseline characteristics including demographic data were described by means, standard deviations (SD), counts, and proportions as dictated by data type. All BPV metrics were categorized into quartiles. We evaluated the association between baseline characteristics and BPV using ordered logistic regression. Backward selection was applied to identify predictors of BPV in multivariable-adjusted models, by removing variables with p-value ≥0.1. We considered two-tailed p-values <0.05 as statistically significant. Further, Analysis of variance (ANOVA) or Kruskal-Wallis test was done to estimate the effects of certain single factors including age, pre-dialysis SBP, antihypertensive treatments, dialysis time, and vascular access on short-term BPV metrics. Kaplan-Meier estimator was used to calculate the cumulative incidence of cardiovascular events and all-cause death in each quartile group of BPV. Three different Cox regression models were used to calculate hazard ratio (HR) with 95% confidence interval (CI): (1) unadjusted, (2) partially adjusted (age, gender, mean baseline pre-dialysis SBP), and (3) completely adjusted (age, gender, weight, body mass index [BMI], smoking, dialysis vintage, antihypertensive therapy, vascular access, dialysis frequency, dialysis time, dialysis session length, dialysate calcium concentration, serum creatinine, ultrafiltration volume, mean baseline pre-dialysis SBP, mean baseline pre-dialysis diastolic blood pressure (DBP), diabetes, serum albumin, hemoglobin, calcium, and PTH). Variables with p-values <0.1 and wellestablished predictors were selected as adjustment covariates in multivariate analyses. We confirmed proportionality assumptions of the Cox regression models using Schoenfeld residual. All analyses were performed using STATA 11.0 MP (StataCorp, www.stata.com).
Results
Study population
A total of 526 HD patients satisfying the inclusion criteria were enrolled in this study. These patients underwent a total of 59, 412 qualifying HD treatments in the first 12 months of baseline visit, during which 297, 060 SBP measurements were recorded. The various baseline characteristics including demographic details, dialysis parameters, Vascular access, comorbidities, laboratory parameters, and medications are presented in Table 1 .
Peridialytic short-term BPV metrics
The observed results for the four short-term BPV metrics are given in Supplementary Table 1 ).
Factors influencing short-term BPV
The association between short-term BPV and cohort characteristics determined by logistic regression analysis revealed that the following five cohort parameters influences BPV metrics: (1) age, (2) predialysis BP, (3) antihypertensive drugs, (4) dialysis time, and (5) vascular access. Apart from these, ultrafiltration volume and serum albumin level also influenced BPV (data not shown). The other cohort parameters did not have statistically significant association with BPV.
Age. Older patients tended to have greater BPV. Subjects older than 55 years had greater SBP CV (0.082 ± 0.021 vs. 0.073 ± 0.018, p<0.001), SBP intradialytic ARV (11.36 ± 2.43 vs. 10.27 ± 2.48 mm Hg, p<0.001), and SBP residual (11.52 ± 2.61 vs. 10.51 ± 2.42 mm Hg, p<0.001) compared with younger patients (Fig. 1A) . Additionally, multifactor logistic regression showed a significant association between age and all four BPV metrics ( Table 2) . (Fig. 1B) . Multifactor logistic regression also suggested pre-dialysis SBP as a significant influencing factor for SBP change (odds ratio [OR]: 0.99, 95% CI: 0.97-1.00), SBP intradialytic ARV (OR: 1.02, 95% CI: 1.01-1.04), and SBP residual (OR: 1.03, 95% CI: 1.02-1.04).
Antihypertensive drugs. This study also revealed drug class-specific effects on BPV independent of pre-dialysis SBP. CCB use was found to be associated with lower SBP CV (0.07 ± 0.02 vs. 0.08 ± 0.02 vs. 0.08 ± 0.02, p=0.002), SBP intradialytic ARV (10.21 ± 2.31 vs. 11.38 ± 2.43 vs. 11.39 ± 2.83 mm Hg, p=0.0498), and SBP residual (10.39 ± 2.15 vs. 11.62 ± 2.48 vs. 11.31 ± 2.45 mm Hg, p=0.017) compared with ACEI/ARBs and non-CCB/ACEI/ARB antihypertensive therapy (Fig. 1C) . Further analysis on the effects of different CCB classes (nifedipine, amlodipine, and other classes of CCBs) showed no significant difference (Fig.  1D ). Multifactor logistic regression suggested an antihypertensive drug class influencing absolute SBP change (Table 2) .
Dialysis time. Dialysis time was found to have an impact on BPV independent of baseline pre-dialysis SBP. Patients dialyzed in the morning had a greater absolute SBP change (-9.75 ± 9.39 mm Hg) than those dialyzed in the afternoon (-5.31 ± 9.07 mm Hg, p<0.001) and evening (-4.20 ± 8.63 mm Hg, p<0.001) (Fig. 1E) . However, SBP residual showed an opposite tendency, lowest in the morning group (10.39 ± 2.39 mm Hg) and higher in the afternoon (11.39 ± 2.61 mm Hg, p<0.001) and evening group (11.29 ± 2.57 mm Hg, p=0.002) (Fig. 1E) . Multifactor logistic regression also showed a significant association between dialysis time and SBP change ( Table 2) .
Vascular access. Subjects dialyzed via arteriovenous fistulas showed a lower BPV than dialyzed with catheters with respect to SBP CV (0.07 ± 0.02 vs. 0.08 ± 0.02, p=0.02), SBP intradialytic ARV (10.61 ± 2.42 vs. 11.34 ± 2.66 mm Hg, p=0.01), and SBP residual (10.64 ± 2.41 vs. 11.91 ± 2.71 mm Hg, p=0.00) (Fig. 1F) . Multifactor logistic regression also showed a significant association between vascular access and SBP intradialytic ARV (OR: 0.70, 95% CI: 0.45-0.89).
Short-term BPV and risk of cardiovascular events and all-cause mortality
During the study period, 27 incidents of death and 92 cardiovascular events were recorded. Cardiovascular disease was the predominant cause of death (40.7%), followed by infections (37.0%) and stroke (14.8%). SBP CV (unadjusted HR: 1.37, 95% CI: 1.14-1.66, p=0.001), SBP intradialytic ARV (unadjusted HR: 1.46, 95% CI: 1.20-1.77, p<0.001), and SBP residual (unadjusted HR: 1.47, 95% CI: 1.21-1.79, p<0.001), which are BPV metrics of higher order, were associated with a greater risk of cardiovascular events (Supplementary Table 2 ). After partial and complete adjustment of other potential confounders, the HR was diminished, but remained statistically significant for SBP intradialytic ARV (HR: 1.31, 95% CI: 1.04-1.66, p=0.024). All the four short-term BPV metrics showed no significant impacts on all-cause mortality. Statistically significant difference was observed between the different quartiles of short-term BPV metrics (except SBP change) and their association with cardiovascular events ( Fig. 2A-2D ). SBP intradialytic ARV Q3 and Q4 had a more linear relationship with cardiovascular events, suggesting the scope of having an SBP intradialytic ARV cutoff for clinical risk assessment. Unadjusted, partially adjusted and completely adjusted HRs for cardiovascular events and all-cause death were shown in Fig. 2E-2F Pre-dialysis SBP, which is a parameter for clinical decision-making in the management of hypertension, was found to be associated with all the four BPV metrics, substantiating its usefulness as a primary metric for hypertension in HD patients, which was earlier endorsed by Shafi et al., 2014 .
The antihypertensive drug class was found to have an effect on BPV metrics, with CCBs being the most effective in controlling the short-term BPV. Similar findings were also made in previous studies with long-term BPV in general population [23, 24] . The observed effects of CCBs in controlling short-term BPV might be due to their vasodilator effects [25] and long half-life [26] as well as the sustained release of CCBs [27] . Further, a previous in vivo experimental study showed a low removal of nifedipine by HD, with a dialyzer extraction ratio of 2.3% ± 0.8% [28] , which could also contribute to the better therapeutic outcome with CCBs in HD patients. Intra-class variability of CCB drugs in alleviating short-term variability in BP was observed in a previous randomized crossover study [29] , which was in contrary to the current study.
It is the first study that showed the association between dialysis time and BPV. Interestingly, morning dialysis showed a higher absolute SBP change but a lower SBP residual. This difference may be attributed to the fact that SBP residual emphasizes on the deviation from a predicted value, whereas SBP change highlights the extreme values. Further experimental studies are needed to determine which time is best for dialysis.
Vascular access also influences short-term BPV metrics, with fistulas performing better in terms of controlling short-term BPV in our study, which is in accordance to a recent study on long-term BPV [12] . It could be due to the greater influence of catheters on hemodynamics than fistulas, implying fistulas to be favorable for vascular access in HD patients.
DBP variability has also been implicated in predicting cardiovascular outcomes in previous studies [30] . However, no such association was found in the current study (data not shown).
Present guidelines for hypertension focuses on average BP which is not constant but fluctuates from time to time, more so in HD patients. In this context, additional metrics specific for HD patients are required. BPV, which describes fluctuation of BP at different levels, may serve as a better indicator of cardiovascular functioning in HD patients. Previous studies have demonstrated both short-and long-term BPV associated with cardiovascular and all-cause mortality in HD patients [11, 13] . In this study, higher short-term BPV was associated with a greater risk of cardiovascular events, which substantiates its importance as a potential marker for cardiovascular health in HD patients.
We compared four BPV metrics, namely, SBP change, SBP CV, SBP intradialytic ARV, and SBP residual. SBP change was least associated with the primary outcomes although a previous retrospective cohort study showed a U-shaped association between SBP change and all-cause mortality, with peak survival at -14 mm Hg [31] . We recommend SBP change to be used as a preliminary measure when intradialytic BP measurements are not available.
Since SBP SD increases with SBP, we chose SBP CV instead of SD as the second metric of interest. On this study, SBP CV is the only short-term metric independent of baseline predialysis SBP and is found to be moderately associated with cardiovascular event risk. Since it is not dependent on pre-dialysis SBP, we suggest this metric be applied when baseline SBP differentiates greatly.
SBP intradialytic ARV, which considers the order of measurements, is the most effective marker for cardiovascular events. As SBP changes from time to time during dialysis sessions, SBP intradialytic ARV may best reflect the absolute fluctuation of SBP during HD. Since BP fluctuations lead to alternating periods of myocardial hypoxia, SBP intradialytic ARV thus becomes a potential predictor of cardiovascular events. Hence, we recommend it as a preferred measure for BP management in HD patients. In this study, the number of SBP measurements used to calculate SBP intradialytic ARV was 5. In a previous study, 48 SBP measurements were recommended for accurate determination of ARV in ABPM without compromising its prognostic value [32] . However, owing to the practical difficulties involved with measuring multiple SBP measurements during dialysis sessions, an optimal value for a minimum number of readings for intradialytic ARV may be arrived at in future. SBP residual derived from generalized models is also a good outcome marker. In the study conducted by Flythe et al., SBP residual is associated with increased all-cause (HR :1.26, 95% CI: 1.08-1.47) and cardiovascular mortality (HR: 1.32, 95% CI: 1.01-1.72) [13] . However, this metric requires complex analytical approaches, making it less practical for clinical use. Besides, as it relies on BP paradigms, it may fail when there is a paradigm shift.
To the best of our knowledge, this is the first cohort study to analyze different shortterm BPV metrics in HD patients, giving clinicians options to choose BPV parameters based on the clinical context and data availability. Further, it is the largest cohort study on BPV in Chinese HD population with the largest intradialytic BP database, giving a picture of BPV in Asian population.
We have to admit that there are still some limitations. First, as with all retrospective cohort studies, bias may exist. We have adjusted confounding variables when evaluating BPV and cardiovascular events, but we cannot dismiss the potential for missing confounders. Second, we evaluated the effects of antihypertensive drugs, but we were unable to assess compliance. Third, as we included patients from 2014, the follow-up time may be too short to estimate the difference in death events according to different BPV quartiles. So, further prospective, randomized, controlled trials with a long follow-up and a large sample size are needed. Future studies aimed at establishing an operational threshold for intradialytic SBP ARV will go a long way in the management of cardiovascular events in HD patients.
Conclusion
This study demonstrated the association of short-term BPV with cardiovascular events, with SBP intradialytic ARV as the best predictor for cardiovascular events, suggesting that it could be a potential marker for amelioration and management of BP in HD patients.
